A rare-disease therapy priced at several hundred thousand dollars a year, or a gene therapy priced in the millions, does not fit the cost-effectiveness thresholds that commercial analytics inherited from common disease. The mismatch is not a detail to negotiate around. It is structural, and the bodies that set the thresholds have already conceded it by writing a separate rulebook for the ultra-orphan case.
The thresholds do not fit, and the assessors say so
In the United Kingdom, NICE runs two different value bars. Its standard appraisal uses a threshold of 20,000 to 30,000 pounds per quality-adjusted life year; its Highly Specialised Technologies route, for very rare conditions, applies 100,000 pounds, rising to 300,000 in defined circumstances. In the United States, ICER built a modified framework for ultra-rare treatments that reports cost-effectiveness out to 500,000 dollars per QALY, several times its standard 50,000 to 150,000 range. When two independent assessors construct a separate threshold for the same category, the standard tool is not being stretched. It is being replaced.
For a one-time cure, the payment model breaks too
Price is only half the problem; the payment structure is the other. A one-time gene therapy priced at 2 to 3 million dollars, like the sickle cell therapies Casgevy and Lyfgenia, asks a payer built to spend a little each year for many years to spend everything at once. The system was not designed for it, and the market has shown what happens: bluebird bio withdrew Zynteglo from Europe in 2021 after payers declined a roughly 1.8 million dollar one-time price. The workable answer is not a lower price but a different deal, an outcomes-based annuity that pays over years and only while the therapy keeps working, the logic behind the US Cell and Gene Therapy Access Model. A value case for a one-time therapy is a financing design, not a QALY calculation.
In the Gulf, the payer is the state
Where the state is the payer, the argument changes again. In the Gulf, government bears most of the orphan-drug cost and also runs the screening that finds the patients, so identification and access are two ends of one budget. The value case is argued on government affordability and on the screening economics that make early treatment cheaper than late, not on a Western cost-per-QALY threshold that no Gulf payer applies. A pricing model lifted from the US or UK misreads the buyer entirely.
The value case is built, not looked up
Ultra-orphan access is where the rare-disease exception becomes explicit. The price is real, the standard threshold does not hold, and for a one-time therapy the deal itself has to be built rather than assumed. This is the access face of the wider rare-disease sizing discipline: the value case, like the market size, is constructed for the therapy and the payer in front of you, not looked up from a common-disease rulebook.
AXLRx builds the ultra-orphan value case market by market, on the right threshold and the right payment model. See the payer and HTA briefs, or commission a model scoped to your asset.